Irish Biotech Firm GH Research Sees Cash Decline in Q2, Advances Psychedelic Drug Trials
Irish Biotech Firm GH Research Sees Cash Decline in Q2, Advances Psychedelic Drug Trials
Irish psychedelic biotech firm GH Research PLC (NASDAQ:GHRS) reported its financial results for the second quarter ended June 30, 2024.
愛爾蘭迷幻生物科技公司GH Research PLC（納斯達克：GHRS）公佈了截至2024年6月30日第二季度的財務業績。
Q2 2024 Financial Highlights
2024年第二季度財務業績亮點
- Cash, cash equivalents, other financial assets and marketable securities were $204.5 million as of June 30, 2024, compared to cash, cash equivalents, other financial assets and marketable securities of $222.7 million as of December 31, 2023.
- Research and development expenses were $9.8 million for the quarter ended June 30, 2024, compared to $7.2 million for the same quarter in 2023.
- General and administrative expenses were $3.5 million for the quarter ended June 30, 2024, compared to $2.7 million for the same quarter in 2023.
- The net loss was $10.4 million, or $0.20 loss per share, for the quarter that ended June 30, 2024, compared to the $7.7 million or $0.15 loss per share for the same quarter in 2023.
- 截至2024年6月30日，現金、現金等價物、其他金融資產和可交易證券爲20450萬美元，而截至2023年12月31日的現金、現金等價物、其他金融資產和可交易證券爲22270萬美元。
- 2024年6月30日結束的季度研發費用爲980萬美元，而2023年同一季度的研發費用爲720萬美元。
- 2024年6月30日結束的季度一般和行政費用爲350萬美元，而2023年同一季度的一般和行政費用爲270萬美元。
- 2024年6月30日結束的季度淨虧損爲1040萬美元，每股虧損0.20美元，而2023年同一季度的淨虧損爲770萬美元，每股虧損爲0.15美元。
Read Also: GH Research: This European Biotech Company Reports Full Year 2023 Financial Results And Business Updates
閱讀更多：GH Research：這家歐洲生物科技公司公佈了2023年全年財務業績和業務更新
Business Update
業務更新
The Dublin-based clinical-stage biopharmaceutical company, which researches treatments for psychiatric and neurological disorders, also provided updates on its business.
這家位於都柏林的臨床階段生物製藥公司，專門研究治療精神疾病和神經疾病的治療方法，也提供了業務的最新資訊。
- Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. If you're serious about the business, you can't afford to miss out.
- 訂閱Benzinga的獨家分析和大麻行業及市場的頭條新聞，並每天免費將其發送到您的電子郵箱。在這裏訂閱我們的通訊。如果您對這個行業很重視，您不能錯過這些信息。
GH Research has two DMT-related drugs that are currently undergoing clinical trials, both based on mebufotenin (5-MeO-DMT), a Schedule I psychedelic which is considered illegal in the U.S.
GH Research擁有兩款與DMT有關的藥物，目前正在進行臨床試驗，兩者都基於甲磺酸硬腦酮（5-MeO-DMT），這是一種美國認定爲非法的I類致幻劑。
GH001, the company's proprietary inhaled mebufotenin product candidate, is being investigated in a multi-center, randomized, double-blind, placebo-controlled Phase 2b trial in roughly 80 patients with treatment-resistant depression (TRD) (GH001-TRD-201) at approximately 20 sites across seven European countries.
GH001是該公司專有的吸入用甲磺酸硬腦酮產品候選藥，正在歐洲7個國家的大約20個研究中心進行大約80名治療抵抗性抑鬱症（TRD）患者的20億二期試驗（GH001-TRD-201）。
GH Research said it continues to recruit according to plan and expects to complete the double-blind phase of this trial in the third quarter of 2024 as well as the 6-month open-label extension in the first quarter of 2025.
GH Research表示，他們將繼續按計劃招募試驗對象，並預計將於2024年第三季度完成該試驗的雙盲階段，以及於2025年第一季度完成爲期6個月的開放標籤延期試驗。
With GH002, its proprietary intravenous mebufotenin (5-MeO-DMT) product candidate, GH Research recently completed a Phase 1, dose-ranging clinical pharmacology trial in healthy volunteers (GH002-HV-105).
GH002是該公司專有的靜脈用甲磺酸硬腦酮（5-MeO-DMT）產品候選藥，GH Research最近在健康志願者中完成了一項第一階段的劑量範圍臨床藥理學試驗（GH002-HV-105）。
The trial showed that GH002 was well-tolerated and produced potent pharmacodynamic (PD) effects, as assessed by psychoactive effect intensity, with an ultra-rapid onset and short-duration psychoactive experience.
試驗結果顯示GH002耐受性良好，併產生了強效的藥效動力學（PD）效應，通過致幻劑效應強度評估，表現出超快的起效作用和短暫的致幻體驗。
- Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
- Psyched：5-MeO-DMt用於治療抑鬱症，猶他州醫院提供療法，馬斯克和Facebook的影響力
譯文內容由第三人軟體翻譯。